Clinical predictors of a positive genetic test in hypertrophic cardiomyopathy in the Brazilian population
1 Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo, São Paulo, Brazil
2 Clinical Unit of Cardiomyopathies, Heart Institute (InCor), University of São Paulo, São Paulo, Brazil
3 Federal University of Espírito Santo, Vitória, Brazil
4 Chagas Disease and Heart Failure Outpatient Service, PROCAPE-University of Pernambuco/UPE, Recife, Brazil
5 Federal University of Amazonas, Manaus, Brazil
BMC Cardiovascular Disorders 2014, 14:36 doi:10.1186/1471-2261-14-36Published: 13 March 2014
Hypertrophic cardiomyopathy is a genetic autosomal dominant disease characterized by left ventricular hypertrophy. The molecular diagnosis is important but still expensive. This work aimed to find clinical predictors of a positive genetic test in a Brazilian tertiary centre cohort of index cases with HCM.
In the study were included patients with HCM clinical diagnosis. For genotype x phenotype comparison we have evaluated echocardiographic, electrocardiographic, and nuclear magnetic resonance measures. All patients answered a questionnaire about familial history of HCM and/or sudden death. β-myosin heavy chain, myosin binding protein C, and troponin T genes were sequenced for genetic diagnosis.
The variables related to a higher probability of a positive genetic test were familial history of HCM, higher mean heart frequency, presence of NSVT and lower age. Probabilities of having a positive molecular genetic test were calculated from the final multivariate logistic regression model and were used to identify those with a higher probability of a positive molecular diagnosis.
We developed an easy and fast screening method that takes into account only clinical data that can help to select the patients with a high probability of positive genetic results from molecular sequencing of Brazilian HCM patients.